Erratum to ‘TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate’ [Clin Microbiol Infect (30) (2024) 743–754]

IF 10.9 1区医学 Q1 INFECTIOUS DISEASES

Clinical Microbiology and Infection Pub Date : 2025-01-01 DOI:10.1016/j.cmi.2024.08.005

María Patricia Hernández-Mitre , Susan C. Morpeth , Balasubramanian Venkatesh , Thomas E. Hills , Joshua Davis , Robert K. Mahar , Grace McPhee , Mark Jones , James Totterdell , Steven Y.C. Tong , Jason A. Roberts

引用次数: 0

查看原文本刊更多论文

用于治疗成人 COVID-19 的 TMPRSS2 抑制剂：萘伐司他和甲磺酸卡莫司他随机临床试验的系统回顾和荟萃分析》的勘误[《临床微生物学与感染》30 (2024) 743-754]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Microbiology and Infection 医学-传染病学

CiteScore

25.30

自引率

2.10%

发文量

441

审稿时长

2-4 weeks

期刊介绍： Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.